Robert Gaudin | Medicine and Health Sciences | Best Researcher Award

Published on 15/07/202615/07/2026 by Research Awards

Best Researcher Award

Robert Gaudin
Affiliation	Charité Berlin
Country	Germany
Scopus ID	56119429900
Documents	41
Citations	1,949
h-index	21
Subject Area	Medicine and Health Sciences
Event	International Research Awards
ORCID	0000-0001-9061-7220

Robert Gaudin
Charité Berlin

The Best Researcher Award recognizes sustained scholarly excellence, impactful scientific publications, and measurable contributions to the advancement of medicine and health sciences. Robert Gaudin, affiliated with Charité Berlin, has established a recognized research profile supported by peer-reviewed publications, international collaborations, and a strong citation record indexed in Scopus. His academic portfolio demonstrates continued engagement in biomedical research and knowledge dissemination, reflecting standards commonly associated with international research recognition.[1]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This article presents an overview of the academic achievements of Robert Gaudin within the field of medicine and health sciences. His scholarly activities include the publication of peer-reviewed research, participation in internationally recognized scientific collaborations, and contributions that have received substantial academic citations. The available bibliometric indicators demonstrate research productivity and influence consistent with internationally recognized standards of scientific excellence.[1]

Keywords

Medicine, Health Sciences, Biomedical Research, Clinical Investigation, Scientific Publications, Citation Analysis, Research Excellence, Academic Recognition

Introduction

Academic recognition awards acknowledge researchers whose work contributes significantly to scientific progress through sustained publication activity, innovation, collaboration, and scholarly influence. Bibliometric indicators such as publication count, citation performance, and the h-index are commonly considered alongside qualitative assessments of research quality and impact. Robert Gaudin’s academic profile aligns with these internationally accepted evaluation principles.[2]

Research Profile

Robert Gaudin is affiliated with Charité Berlin, one of Europe’s leading academic medical institutions. His Scopus profile records 41 indexed publications that have accumulated approximately 1,949 citations, resulting in an h-index of 21. These indicators suggest consistent scholarly productivity and a sustained influence within the biomedical research community.[1]

Research Contributions

The research contributions attributed to Robert Gaudin encompass peer-reviewed investigations, interdisciplinary collaborations, and scientific communication within medicine and health sciences. His publications contribute to expanding evidence-based knowledge while supporting international scientific dialogue. The measurable citation performance indicates that his work has been referenced by researchers across multiple studies, reflecting continued academic relevance.[1][3]

Publications

Robert Gaudin has authored and co-authored numerous peer-reviewed publications indexed in international bibliographic databases. His publication record demonstrates active participation in biomedical research and collaborative scientific projects. Several publications are associated with persistent digital object identifiers (DOIs), ensuring permanent accessibility and citation tracking across scholarly databases.[3]

Research Impact

Citation-based metrics indicate that Robert Gaudin’s research has achieved substantial visibility within the international scientific community. His h-index of 21 and citation count approaching two thousand demonstrate that multiple publications have influenced subsequent research. These bibliometric indicators are frequently considered alongside research quality, originality, and scientific significance during academic evaluation processes.[1][2]

Award Suitability

Based on publicly available bibliometric information, Robert Gaudin demonstrates characteristics commonly associated with candidates for international academic recognition. His publication record, citation performance, institutional affiliation, and continued contribution to medicine and health sciences provide objective indicators that support consideration for the Best Researcher Award presented during the International Research Awards.[1]

Conclusion

Robert Gaudin’s academic profile reflects sustained scholarly productivity, measurable citation impact, and active participation in medicine and health sciences research. His contributions illustrate the importance of rigorous scientific investigation, peer-reviewed publication, and international collaboration. Collectively, these characteristics represent the type of academic excellence recognized by international research award programs.[1]

External Links

References

Elsevier. (2026). Scopus author details: Robert Gaudin, Author ID 56119429900. Scopus.https://www.scopus.com/authid/detail.uri?authorId=56119429900
ORCID. (2026). Robert Gaudin ORCID Record.https://orcid.org/0000-0001-9061-7220
AI-Powered Identification of Osteoporosis in Dental Panoramic Radiographs: Addressing Methodological Flaws in Current Research https://www.mdpi.com/2075-4418/14/20/2298
International Research Awards. Official Award Website.https://researchawards.net/

Alessandra Franco | Biomedical Engineering | Best Researcher Award

Published on 24/06/202624/06/2026 by Research Awards

Best Researcher Award

Alessandra Franco
University of Naples Federico II, Italy

Alessandra Franco
Affiliation	University of Naples Federico II
Country	Italy
Scopus ID	59349375600
Documents	7
Citations	35
h-index	3
Subject Area	Biomedical Engineering
Event	International Research Awards
ORCID	0009-0004-2326-2895

Alessandra Franco is an emerging researcher in Biomedical Engineering at the University of Naples Federico II. Her academic activities focus on digital health technologies, artificial intelligence applications in medicine, biomedical signal analysis, and healthcare innovation. Through interdisciplinary collaborations, she has contributed to studies addressing telemedicine, diagnostic imaging, and neurological assessment methodologies. Her scholarly profile demonstrates a commitment to evidence-based research and international scientific engagement.[1]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This article presents an academic overview of Alessandra Franco and her contributions within Biomedical Engineering. Her research activities span telemedicine, deep learning, digital diagnostics, and biomedical data interpretation. Published studies demonstrate an interest in translating computational methodologies into practical healthcare applications. These contributions support the advancement of modern clinical technologies and patient-centered healthcare solutions.[2]

Keywords

Biomedical Engineering, Telemedicine, Digital Health, Deep Learning, Medical Imaging, Healthcare Innovation, Parkinson’s Disease Analysis, Artificial Intelligence in Medicine, Gait Assessment, Diagnostic Technologies.

Introduction

Biomedical Engineering continues to transform healthcare through technological innovation and interdisciplinary collaboration. Alessandra Franco’s work reflects this evolution by exploring advanced computational tools for medical diagnostics and healthcare delivery. Her publications address contemporary challenges associated with remote healthcare, intelligent analysis systems, and clinical decision support. Such research contributes to the broader development of data-driven medicine.[3]

Research Profile

Alessandra Franco is affiliated with the Department of Electrical Engineering and Information Technology at the University of Naples Federico II. Her academic background includes undergraduate and postgraduate studies in Biomedical Engineering, followed by doctoral research activities. Her profile highlights participation in multidisciplinary projects involving healthcare technologies and medical data analysis. These experiences have strengthened her research capabilities across clinical and engineering domains.[1]

Research Contributions

Her research contributions include investigations into telemedicine infrastructures, artificial intelligence frameworks, and diagnostic image processing. Published work has examined healthcare accessibility through 5G-enabled systems and evaluated machine learning approaches for disease assessment. Additional studies explore denoising techniques in mammography and data-driven approaches to neurological monitoring. Collectively, these efforts contribute to improving healthcare efficiency and clinical interpretation.[2][4]

Publications

The publication record of Alessandra Franco demonstrates consistent engagement with peer-reviewed biomedical research. Her studies have appeared in recognized journals including Sensors, Scientific Reports, and Bioengineering, covering topics such as Parkinson’s disease assessment, digital mammography enhancement, and telemedicine applications. These publications illustrate a growing scholarly presence and an ongoing commitment to advancing biomedical knowledge through rigorous scientific investigation.[3][4][5]

Research Impact

The impact of her research is reflected through citations, collaborative publications, and relevance to current healthcare challenges. By integrating computational intelligence with biomedical practice, her work supports more efficient diagnostic processes and patient monitoring strategies. Research outcomes provide useful perspectives for clinicians, engineers, and healthcare administrators. These contributions align with the increasing demand for technology-assisted healthcare systems.[5]

Award Suitability

Alessandra Franco demonstrates qualities associated with candidates for academic recognition through sustained research activity and interdisciplinary collaboration. Her work addresses important topics in healthcare innovation and biomedical technology. The combination of scholarly publications, international visibility, and scientific relevance supports consideration for professional distinction. These characteristics align with the objectives of the International Research Awards program.

Conclusion

Alessandra Franco represents a developing research profile within Biomedical Engineering, supported by meaningful contributions to digital healthcare and medical technology. Her publications demonstrate scientific rigor and interdisciplinary engagement. Continued research activity is expected to further expand her impact within the biomedical community. The available evidence supports recognition of her scholarly achievements and future potential.

External Links

References

ORCID. (2026). Alessandra Franco (ORCID: 0009-0004-2326-2895).
https://orcid.org/0009-0004-2326-2895
Franco, A., Angelone, F., Calderone, D., Ponsiglione, A. M., Romano, M., Ricciardi, C., & Amato, F. (2026). Telemedicine and 5G Technologies: A Systematic Global Review of Applications over the Past Decade. Bioengineering.
https://doi.org/10.3390/bioengineering13040438
Franco, A., Russo, M., Amboni, M., Ponsiglione, A. M., Di Filippo, F., Romano, M., Amato, F., & Ricciardi, C. (2024). The Role of Deep Learning and Gait Analysis in Parkinson’s Disease: A Systematic Review. Sensors.
https://doi.org/10.3390/s24185957
Angelone, F., Franco, A., Ponsiglione, A. M., Ricciardi, C., Belfiore, M. P., Gatta, G., Grassi, R., Sansone, M., & Amato, F. (2025). Assessment of an Unsupervised Denoising Approach Based on Noise2Void in Digital Mammography. Scientific Reports.
https://doi.org/10.1038/s41598-025-19499-1
Elsevier. (n.d.). Scopus Author Details: Alessandra Franco, Author ID 59349375600. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=59349375600

Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on 02/12/202502/12/2025 by Research Awards

Prof. Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

The Second Affiliated Hospital of Nanchang University | China

Dr. Hou-Qun Ying, PhD, born on July 18, 1985, in Shangrao, Jiangxi Province, China, is an accomplished clinical scientist specializing in cancer biomarkers, inflammation-related indices, molecular epidemiology, and therapeutic response prediction. He currently serves as the Vice Director of the Department of Clinical Laboratory Medicine at The Second Affiliated Hospital of Nanchang University, where he plays a leading role in translational research, diagnostic innovation, and clinical laboratory management. Dr. Ying earned his Ph.D. in Clinical Laboratory Diagnosis from Southeast University (2013–2016), after completing his Master of Medicine in Pathogenic Biology at Dali University and his Bachelor of Medicine in Medical Laboratory Science from Tianjin Medical University. His academic and professional journey reflects strong expertise in cancer diagnostics, genetic polymorphisms, biomarker development, and precision medicine. Dr. Ying has successfully led multiple competitive research grants, including the National Natural Science Foundation of China Youth Fund (2018–2020), exploring Hippo-pathway-related genetic variations and EGFR-TKI resistance in non-small cell lung cancer, and the 2024–2027 Regional Fund focusing on SP1 transcription factor–related genetic variations as biomarkers for bevacizumab resistance in metastatic colorectal cancer. His research contributions span more than 70 peer-reviewed publications, with many as first, co-first, or corresponding author in high-impact journals such as Scientific Reports, Oncotarget, Cancer Medicine, Therapeutic Advances in Medical Oncology, Frontiers in Oncology, Pharmacological Research, Biomarkers, Future Oncology, and J Inflammation Research. His studies have provided pivotal insights into inflammatory markers such as fibrinogen-to-pre-albumin ratio, albumin-to-fibrinogen ratio, dNLR, PLR, and novel composite biomarkers for cancer prognosis, treatment response prediction, early diagnosis, and recurrence risk stratification. He has also made influential contributions to colorectal cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma, and NSCLC through biomarker innovation, clinical prediction models, and meta-analytic evaluations. As a corresponding author, Dr. Ying has developed and validated numerous inflammation-based and genetic biomarker signatures, such as FPR, ADS score, MLPAS, CCMLP, and chronic inflammation indices, improving precision therapeutic decisions for chemotherapy, bevacizumab, 5-FU–based regimens, and TKIs. Additionally, his collaborative work extends to machine learning applications in early gastric cancer prediction, molecular mechanisms underlying cancer progression, and multi-omics approaches. With a distinguished record of scientific leadership, grant success, and impactful publications, Dr. Ying continues to advance clinical oncology diagnostics and personalized treatment strategies through rigorous research, innovation, and interdisciplinary collaboration.

Profiles: Scopus | Orcid

Featured Publications

Peng, Y., Shang, R., Wang, Z.-J., Ye, Q.-Y., Tang, X.-Y., Cheng, X.-X., & Ying, H.-Q. (2025). Chronic inflammatory comprehensive signature predicts oxaliplatin and 5-fluorouracil benefit in early colorectal cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S556619

Lu, Y., Ye, Q.-Y., Mei, O., Li, Y.-N., Peng, Y., Ying, H.-Q., & Cheng, X.-X. (2025). Chronic inflammation index-based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage II–III colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S517378

Ye, Q.-Y., Wang, Y.-Y., Wang, Z.-J., Lu, M., Peng, H.-X., Wang, X., Cheng, X.-X., & Ying, H.-Q. (2025). Robust predictive performance of MLPAS and CCMLP for clinical outcome and risk stratification in patients with colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S498028

Tian, H., Liu, Z., Zhang, Z., Zhang, L., Zong, Z., Liu, J., Ying, H., & Li, H. (2023). Clinical significance of fibrinogen and platelet to pre-albumin ratio in predicting the prognosis of advanced gastric cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S412033

Ying, H.-Q., Liao, Y.-C., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X.-X. (2021). Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naïve patients with advanced NSCLC. Pharmacological Research, 105734. https://doi.org/10.1016/j.phrs.2021.105734

Ying, H.-Q., You, X.-H., Liao, Y.-C., Sun, F., & Cheng, X.-X. (2021). High-grade inflammation attenuates chemosensitivity and confers poor survival of surgical stage III CRC patients. Frontiers in Oncology, 11, 580455. https://doi.org/10.3389/fonc.2021.580455

Liao, Y.-C., Ying, H.-Q., Huang, Y., Luo, Y.-R., Xiong, C.-F., Nie, R.-W., Li, X.-J., & Cheng, X.-X. (2021). Role of chronic inflammatory ratios in predicting recurrence of resected patients with stage I–III mucinous colorectal adenocarcinoma. Cancer Management and Research, 13, 303758. https://doi.org/10.2147/CMAR.S303758

Thierry Ngouana Kammalac | Medical Mycology | Best Research Article Award

Published on 21/11/202521/11/2025 by Research Awards

Dr. Thierry Ngouana Kammalac | Medical Mycology | Best Research Article Award

Laboratoire Sion| Cameroon

Dr. Ngouana Kammalac Thierry is an accomplished Cameroonian biochemist and medical mycologist with extensive experience in microbial diagnostics, infectious disease research, and biotechnology innovation. He holds a PhD in Biochemistry and Health Sciences (2014), jointly awarded by the University of Montpellier in France and the University of Yaoundé I in Cameroon, where his doctoral work focused on the genetic diversity of Cryptococcus and Candida isolates in HIV-positive patients and their susceptibility to antifungal therapies and medicinal plant extracts. He also holds a Master’s degree in Biochemistry (2009) from the University of Yaoundé I. Dr. Ngouana has built an exceptional career at the intersection of laboratory science, diagnostic technology, and academic instruction. As Director of Zion Biomedical Corporation since 2023, he leads the development and large-scale production of innovative biomedical products, including lateral flow immunochromatographic diagnostic tests, microbial culture media, and specialized staining dyes, contributing to improved diagnostic capacities in the region. Since 2016, he has also served as Director of Zion Medical Laboratory, where he oversees scientific development, clinical diagnostics, and antimicrobial resistance surveillance. His laboratory plays a crucial role in cryptococcal meningitis diagnosis among HIV-infected patients, the establishment of microbial standard operating procedures (SOPs), and the strengthening of Cameroon’s diagnostic infrastructure. Alongside his laboratory leadership, Dr. Ngouana has been an associate lecturer at the Catholic University and the Protestant University of Central Africa since 2015, teaching courses in medical mycology, biochemistry, and bacteriology. He has a strong publication record, contributing to high-impact research on Candida genetic diversity, antifungal resistance, pathogenic yeast epidemiology, and bioactive compounds from medicinal plants. His work has appeared in reputable journals such as Brazilian Journal of Microbiology, American Journal of Microbiological Research, Mycoses, Journal de Mycologie Médicale, Medical Mycology, and Journal of Medical Microbiology. Notable contributions include studies revealing novel genotypes of Candida species, antifungal susceptibility patterns in Africa and Europe, and plant-derived compounds with potent antifungal activity. Dr. Ngouana’s expertise spans molecular diagnostics, PCR, microscopy, microbial culture, infection control, and data analysis, supported by strong research methodology and teamwork competencies. He is an active member of the FAILSAFE Medical Mycology Network, the Cameroonian Society of Microbiology, and the French Society of Medical Mycology, reflecting his engagement in global scientific collaboration and capacity building in medical mycology.

Profiles: Scopus | Orcid

Featured Publications

Ngouana, T. K., Dougue, A. N., Ngouana, V., Tsayem, R. F., Mahamat, Y. H., Boyom, F. F., & Ranque, S. (2025). Vulvo-vaginal candidiasis at the Zion Clinical Laboratory (Yaounde-Cameroon): Risk factors, species distribution and antifungal susceptibility testing. Journal of Medical Mycology,

Kountchou, C. L., Kabtani, J., Dougue, A. N., Nangwat, C., Ekpo, A. I., Ngonde, M. C., Mogo, C. B., Dzoyem, J. P., Ranque, S., & Ngouana, T. K. (2025). Candida krusei (Pichia kudriavzevii) multilocus sequence typing and antifungal susceptibility profile in Cameroon. Brazilian Journal of Microbiology.

Jitendra Patil | Health Sciences | Best Researcher Award

Published on 19/08/202519/08/2025 by Research Awards

Mr. Jitendra Patil | Health Sciences | Best Researcher Award

Mr. Jitendra Patil | Sankalchand Patel University Visnagar,Badoda | India

Mr. Jitendra Hilal Patil, Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, is a PCI-registered academic with a strong background in pharmaceutical sciences and nanotechnology. He holds an M.Pharm in Quality Assurance and is pursuing his Ph.D. at Sankalchand Patel University, Visnagar. His research focuses on developing pH-responsive nanocarrier drug delivery systems for targeted cancer therapy, with publications in Scopus-indexed journals and one patent under process. With a citation index of 29, his innovative work contributes significantly to advancing precision medicine while minimizing systemic toxicity in anticancer treatments.

Author Profile

Scopus

Education

From the very beginning of his educational journey, Mr. Jitendra Hilal Patil demonstrated a keen interest in pharmaceutical sciences and biomedical research. His strong academic foundation was built through consistent excellence across secondary and higher secondary education, which he pursued with dedication and discipline. His pursuit of a Bachelor’s and Master’s degree in Pharmacy further sharpened his knowledge in drug formulation, quality assurance, and advanced pharmaceutical principles. These formative academic years not only shaped his scientific mindset but also ignited his passion for research in nanotechnology and innovative drug delivery systems. His pursuit of a Ph.D. reflects his commitment to expanding the boundaries of knowledge and contributing to global healthcare challenges.

Experience

Mr. Patil serves as a Lecturer at H.R. Patel Institute of Pharmaceutical Education and Research, Shirpur, where he plays a pivotal role in nurturing future pharmacists and researchers. His teaching approach integrates theory with practical insights, encouraging students to think critically about real-world healthcare challenges. Alongside his teaching responsibilities, he actively engages in research, ensuring his academic contributions are aligned with the latest developments in pharmaceutical innovation. His ability to balance teaching, research, and mentoring highlights his versatility as both an educator and a researcher. He also ensures his students are exposed to cutting-edge topics such as nanotechnology, targeted therapies, and drug delivery systems, preparing them to excel in the evolving landscape of pharmaceutical sciences.

Research Focus

The hallmark of Mr. Patil’s academic journey lies in his research on pH-responsive nanocarrier drug delivery systems designed for targeted cancer treatment. Recognizing the limitations of conventional chemotherapy—such as poor survival rates, systemic toxicity, and severe side effects—he focused on developing titanium-based metal-organic frameworks (Ti-MOFs) as nanocarriers for the anticancer drug axitinib (AXT).

Through advanced hydrothermal synthesis and characterization techniques, he successfully developed stable, porous nanostructures that exhibit excellent pH-responsive behavior. His in vitro studies revealed that these carriers released minimal drug amounts in neutral pH, simulating healthy tissues, but significantly increased release in acidic environments mimicking cancer cells. This innovation represents a major step toward precision medicine, offering the potential to reduce toxicity and enhance therapeutic efficacy. His work exemplifies how nanotechnology can transform oncology treatments, opening doors to more effective and patient-friendly therapies.

Awards and Recognition

Mr. Patil’s research has garnered recognition through Scopus-indexed publications, citations, and a patent under process, highlighting the originality and applicability of his work. With a citation index of 29, his publications demonstrate a meaningful academic impact and a growing influence in the pharmaceutical research community. He is also a registered member of the Pharmacy Council of India (PCI), further strengthening his professional credibility. While he has not yet accumulated multiple industry consultancy projects or editorial appointments, his promising work and contributions reflect the qualities of a rising researcher who is set to achieve even greater recognition at both national and international levels.

Impact and Influence

The potential impact of Mr. Patil’s research extends beyond academia, offering transformative possibilities in cancer treatment. By addressing the challenges of drug toxicity and inefficient targeting, his nanocarrier-based system has the potential to improve the quality of life for patients undergoing therapy. Moreover, his contributions set a strong foundation for future collaborations in nanomedicine, oncology research, and pharmaceutical technology. His influence also extends to his students, who benefit from his mentorship, guidance, and emphasis on research-driven learning. By bridging the gap between classroom knowledge and practical innovation, he inspires a new generation of pharmaceutical professionals to pursue impactful research that addresses pressing healthcare challenges.

Publications

Nonlocal thermoelastic diffusion analysis in a semi-infinite body subjected to thermal loading with memory effects.

Author: Jitendra Patil, Chandrakant Jadhav, Nitin Chandel & Vinod Varghese
Journal: Archive of Applied Mechanics
Year: 2025

Development and Characterization of AXT@Metal-Organic Framework: A Biocompatible, pH-Responsive Nanocarrier for Targeted Axitinib Delivery in MCF-7 Cancer Cells.

Author: Jayvadan K. Patel, Ujashkumar A. Shah, Pravin O. Patil, Jitendra H. Patil
Journal: Annales Pharmaceutiques Françaises
Year: 2025

Conclusion

Mr. Jitendra Hilal Patil exemplifies the qualities of a dedicated educator, an emerging researcher, and an innovator in pharmaceutical sciences. His academic journey, professional commitments, and research on pH-responsive nanocarriers reflect not only his scientific expertise but also his vision for improving global healthcare outcomes. With a growing body of impactful publications, a patent under process, and recognition as a promising voice in nanotechnology and drug delivery research, he continues to inspire both peers and students alike. Looking forward, his unwavering dedication positions him to make enduring contributions that bridge cutting-edge research with tangible benefits for society, leaving a meaningful legacy in academia and beyond.

Dengning Xia | Pharmacology | Best Researcher Award

Published on 05/06/202505/06/2025 by Research Awards

Prof. Dengning Xia | Pharmacology | Best Researcher Award

Prof. Dengning Xia, Sun Yat-sen University, China

Dr. Dengning Xia is an Associate Professor and Principal Investigator at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, China. With a Ph.D. in Pharmaceutics and international training experience in Denmark and the U.S., his research focuses on industrial pharmaceutics, biopharmaceutics, and biomedical engineering for drug and vaccine delivery. His work explores microneedle systems, nucleic acid and oral delivery, and translational drug formulation. He has received numerous talent awards, serves on editorial boards of leading journals, and has published over 40 peer-reviewed papers in top-tier pharmaceutical and biomedical journals.

Author Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Dengning Xia’s academic journey reflects a strong and consistent commitment to the pharmaceutical sciences. He began his higher education with a Bachelor’s degree in Pharmacy from the School of Pharmacy, Hunan University of Chinese Medicine in 2005. Demonstrating early promise and dedication, he continued his studies with a Master’s degree in Pharmaceutics from West China School of Pharmacy, Sichuan University (2005–2008), a program known for its rigorous training and focus on drug delivery systems. Pushing the boundaries of academic excellence, Dr. Xia earned his Ph.D. in Pharmaceutics from Shenyang Pharmaceutical University (2008–2011). As part of his doctoral training, he participated in a joint research program at the University of Copenhagen in Denmark (2011), gaining valuable international research exposure and advancing his expertise in advanced drug delivery systems. His early academic experiences laid the foundation for a research career focused on innovation in pharmaceutical technologies.

🧪 Professional Endeavors

Dr. Xia’s professional journey spans globally recognized institutions and industry positions, reflecting his deep-rooted experience across both academic and applied pharmaceutical sciences. Following a brief stint as Formulation Project Leader at Shanghai Haini Pharmaceutical Co., Ltd. (2011–2012), he moved into academia and research as a Postdoctoral Fellow and later Associate Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (2012–2017). His passion for translational research took him to the United States, where he worked at the University of Connecticut and later as a Postdoctoral Fellow and Research Scientist at the School of Chemical and Biomolecular Engineering, Georgia Institute of Technology (2017–2020). Since 2020, Dr. Xia has been serving as an Associate Professor (PI) at the School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, a role he assumed under the prestigious “Hundred Talents Program.”

🔬 Contributions and Research Focus

Dr. Xia’s research spans industrial pharmaceutics, biopharmaceutics, and biomedical engineering, with a consistent focus on overcoming biological barriers in drug and vaccine delivery. His multidisciplinary work has led to impactful contributions in the following areas:

🧬 Overcoming Biological Barriers in Drug Delivery: He has developed innovative microneedle technologies, gastrointestinal and ocular drug delivery systems, and long-acting formulations that enhance therapeutic efficacy while minimizing toxicity.
💉 Vaccine and Nucleic Acid Delivery Systems: Leveraging cutting-edge piezoelectric systems and novel carriers, Dr. Xia is pioneering advancements in gene and vaccine delivery platforms, including low-cost electroporators and skin-based delivery.
🏥 Clinical Translation: His translational research bridges laboratory discoveries with clinical applications, facilitating the development of scalable pharmaceutical formulations and devices.

With over 40 high-impact publications, including in PNAS, Advanced Functional Materials, Journal of Controlled Release, and Science Robotics, Dr. Xia’s work is globally cited and well-respected.

🏆 Accolades and Recognition

Dr. Xia’s innovative work has earned him numerous awards and prestigious appointments:

“Pearl River Talents Program” Young Top-notch Talent – Guangdong Province
Pengcheng Peacock Plan – High-level Talent, Shenzhen
Outstanding Young Talent – Sanofi-CAS Shanghai Institute of Biological Sciences
Youth Innovation Promotion Association Member – Chinese Academy of Sciences

He serves on editorial boards for top journals such as the European Journal of Pharmaceutics and Biopharmaceutics and Asian Journal of Pharmaceutical Sciences, and is a trusted peer reviewer for over 10 major journals and national grant programs.

🌍 Impact and Influence

Dr. Xia’s work has significantly advanced the field of drug delivery science, particularly through his innovations in microneedle patches, oral and ocular formulations, and nucleic acid therapeutics. His research not only addresses practical clinical challenges but also offers low-cost, accessible solutions for global healthcare, such as vaccine patches for diseases like SARS-CoV-2 and Ebola. His collaborative projects with international scientists from the U.S., China, and Europe have amplified his impact, making him a key influencer in pharmaceutical formulation research and a valuable mentor to the next generation of scientists.

🧭 Legacy and Future Contributions

Looking ahead, Dr. Xia’s legacy will likely be defined by his ability to combine academic rigor with real-world solutions. His contributions to microneedle-based technologies and oral delivery systems are poised to transform how vaccines and drugs are administered, especially in low-resource settings. As a principal investigator and educator at Sun Yat-sen University, he continues to mentor emerging scientists, foster international collaborations, and push the boundaries of what’s possible in drug delivery science. With his track record, Dr. Xia is set to play a leading role in the next generation of pharmaceutical innovation, particularly in the realms of biodegradable drug carriers, smart delivery systems, and personalized medicine.

✍️Publication Top Notes

📘Preparation of stable nitrendipine nanosuspensions using the precipitation–ultrasonication method for enhancement of dissolution and oral bioavailability

Author: D Xia, P Quan, H Piao, H Piao, S Sun, Y Yin, F Cui

Journal: European journal of pharmaceutical sciences

Year: 2010

📘Devices, Systems, and Methods for Facilitating Tissue Delivery of Drug

Author: MS Bhamla, G Byagathvalli, D Xia, MR Prausnitz

Journal: US Patent App

Year: 2023

📘Inflammation-retentive hyaluronic acid-mesalamine conjugate for enhanced oral therapy in ulcerative colitis

Author: Y Hou, J Yao, J Hu, D Xia

Journal: International Journal of Biological Macromolecules

Year: 2025

Pratiksha Kshirsagar | Pre-clinical pharmacology | Best Researcher Award | 13450

Published on 31/05/202531/05/2025 by Research Awards

Ms. Pratiksha Kshirsagar | Pre-clinical pharmacology | Best Researcher Award

Ms. Pratiksha Kshirsagar, University of Nebraska Medical Center, United States

Ms. Pratiksha Kshirsagar is a dedicated pharmaceutical scientist currently pursuing her Ph.D. in Pharmaceutical Sciences at the University of Nebraska Medical Center (UNMC), USA. With strong academic credentials and hands-on research experience in both India and the U.S., she specializes in bioanalytical method development, preclinical pharmacokinetics, and drug delivery systems. Her work includes the development and validation of LC-MS/MS methods and conducting in vitro and in vivo DMPK studies for novel therapeutics targeting medulloblastoma. She has co-authored several peer-reviewed publications and presented her findings at national and international conferences. Ms. Kshirsagar is also a recipient of the UNMC Dean of Graduate Studies Conference Attendance Award and remains committed to advancing pharmaceutical research and translational drug development.

Profile

ORCID

🎓 Early Academic Pursuits

Pratiksha Kshirsagar’s academic journey is marked by consistent dedication and a keen interest in pharmaceutical sciences. Her educational foundation was laid at Savitribai Phule Pune University, where she earned both her Bachelor of Pharmacy (2016–2020) with an SGPA of 7.7/10 and a Master of Pharmacy in Pharmaceutics (2020–2022), graduating with distinction (SGPA: 8.96/10). These formative years laid the groundwork for her strong research acumen and laboratory skills. Keen to explore further, she transitioned to the University of Nebraska Medical Center (UNMC), USA, where she pursued a Master of Pharmaceutical Sciences (2022–2024). Her academic growth culminated in her enrollment in the Ph.D. program in Pharmaceutical Sciences (2024–2029). With a GPA of 3.6/4.0, her progress has been both steady and impressive. Simultaneously, she earned a Certificate in Applied Biostatistics with a perfect GPA of 4.0/4.0, showcasing her commitment to interdisciplinary learning and data-driven research.

🧪 Professional Endeavors

Pratiksha’s professional experience is deeply intertwined with her academic path, reflecting a rare blend of scholarly rigor and hands-on application. At UNMC, under the mentorship of Dr. Daryl J. Murry, she has worked extensively as a graduate research assistant and student researcher, contributing to the development and validation of LC-MS/MS bioanalytical methods for novel small molecules and RIPTACs. Her earlier professional journey in India involved impactful research under Dr. Smita S. Pimple, where she explored micro-emulsions using essential oils and carrier oils for skincare applications. This early exposure to formulation science, coupled with analytical chemistry, gave her a solid foundation in pharmaceutics and laboratory research.

🔬 Contributions and Research Focus

Pratiksha’s primary research focus lies in drug metabolism and pharmacokinetics (DMPK), with an emphasis on preclinical evaluation of novel therapeutic agents. Her notable contributions include the in-depth pharmacokinetic analysis of EPZ015666 and JNJ-64619178 for medulloblastoma treatment, reflecting her role in advancing pediatric cancer therapy.

Her technical expertise spans several key areas:

LC-MS/MS bioanalytical method development
In-vitro studies like metabolic stability, protein binding, and drug transporter assays
In-vivo animal studies, including oral/IV dosing and tissue distribution
Use of Phoenix WinNonlin, GraphPad Prism, and other analytical tools for pharmacokinetic modeling

Moreover, she contributed to the design, characterization, and stability testing of advanced nano drug delivery systems such as S-SNEDDS (Solid Self-Nanoemulsifying Drug Delivery System), which demonstrates her interdisciplinary knowledge.

🏅 Accolades and Recognition

Pratiksha’s dedication has earned her notable recognition throughout her academic and research journey. She was awarded the UNMC Dean of Graduate Studies Conference Attendance Award in 2023, underscoring her academic excellence and potential for contribution at scientific forums.

She actively participated in esteemed conferences such as:

American Association of Pharmaceutical Scientists (AAPS), Oct 2023
UNMC College of Pharmacy Research Day, May 2023
CHRI Pediatric Research Forum, May 2023

In earlier academic years, she was involved in state and national level conferences and poster competitions, including the Medical Coding & E-Poster Competition (2020) and a State Level Seminar on Natural Products Research (2018).

🌍 Impact and Influence

Pratiksha’s research holds real-world significance. Her work on small molecule therapeutics for medulloblastoma contributes to the body of knowledge addressing rare pediatric brain cancers, potentially guiding future clinical interventions. Her cross-functional approach—merging analytical chemistry, pharmacology, and pharmaceutical formulation—makes her an invaluable contributor to translational medicine. She has also co-authored several scholarly publications and book chapters on nanotechnology, drug delivery, and antiviral drug challenges, reinforcing her growing influence in the academic community. These contributions are cited in peer-reviewed journals and academic textbooks, evidencing her thought leadership.

🔮 Legacy and Future Contributions

As Pratiksha continues her Ph.D. journey, her trajectory suggests a future as a leading scientist in pharmaceutical research and drug development. Her interests align with solving complex challenges in drug delivery, pharmacokinetics, and personalized medicine. Looking ahead, she aims to bridge the gap between bench-side research and bedside applications, translating scientific breakthroughs into therapeutic realities. Whether in academia, industry, or clinical collaborations, her vision is clear: to contribute meaningfully to global health innovation.

📄 Publication Top Notes

Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies

Contributors: Ling Ding; Pratiksha Kshirsagar; Prachi Agrawal; Daryl J. Murry

Journal: Pharmaceutics

Year: 2025

Preparation and Characterization of Advanced Nano medicine For Malaria: Box Behnken Design Approach

Contributors: Anuradha G. More; Parag R. Potbhare; Padmaja S. Kore; Praveen D. Chaudhari; Pratiksha U. Kshirsagar; Radhika R. Baheti; Surbhi C. Gupta

Journal: International Journal of Life Science and Pharma Research

Year: 2022

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Published on 19/07/202419/07/2024 by Research Awards

Ferdinando D’Amico | Medicine and Health Sciences | Best Researcher Award

Dr Ferdinando D’Amico, IRCCS San Raffaele Hospital, Italy

Dr. Ferdinando D’Amico is a distinguished gastroenterologist at IRCCS San Raffaele Hospital in Milan, Italy, with expertise in gastroenterology and endoscopy. 🎓 He completed his residency in Gastroenterology/Digestive Diseases and earned his PhD at Hunimed University, focusing on histology in inflammatory bowel diseases. His academic journey includes a degree in Medicine and Surgery from “Cattolica del Sacro Cuore” University, where he researched intestinal permeability and atherosclerosis. 🏥 His training included internships in gastroenterology and cardiology at “Agostino Gemelli” Hospital in Rome. Dr. D’Amico is proficient in English and French, and skilled in digital communication. 🌍🔬

Publication profile

Scopus

Education

🎓 From 2003 to 2008, attended Classical High School, graduating with highest honours. From 2009 to 2015, pursued a Degree in Medicine and Surgery at “Cattolica del Sacro Cuore” University, Rome, also graduating with highest honours. 🏆 The dissertation, titled “Alterations in Intestinal Permeability and Inflammation: A Novel Potential Mechanism of Atherosclerosis,” was supervised by Professor Filippo Crea. 📜 Currently registered with the Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Caserta, registration number 7593. 🩺

Experience

From November 1, 2016, to November 2, 2020, [Name] completed their residency in Gastroenterology/Digestive System Diseases at Hunimed University in Pieve Emanuele, Italy, graduating with highest honors. They then pursued a Ph.D. at the same institution, focusing on “The Role of Histology in Inflammatory Bowel Diseases,” under the guidance of Prof. Silvio Danese. From January 1, 2021, to February 9, 2024, they worked as a Gastroenterologist at the IRCCS San Raffaele Hospital in Milan, Italy, in the Gastroenterology and Endoscopy Unit, also directed by Prof. Silvio Danese. 🏥📚🩺

Research focus

Based on the provided publications, the research focus appears to be on inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis. The studies address various aspects such as comparing treatments (e.g., tofacitinib vs. ustekinumab), assessing remission through non-invasive methods, and evaluating regulatory guidance for JAK inhibitors. The research also explores the use of biologics and other therapies in managing IBD, including switching between different treatment forms. This indicates a strong emphasis on optimizing treatment strategies and improving patient outcomes in IBD. 🌟📚💊